James R. Kasinger - Mar 14, 2025 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role
General Counsel and Secretary
Signature
Elizabeth Ryland Waldinger, attorney-in-fact
Stock symbol
CRSP
Transactions as of
Mar 14, 2025
Transactions value $
$0
Form type
4
Date filed
3/18/2025, 05:35 PM
Previous filing
Mar 12, 2025
Next filing
Mar 24, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRSP Stock Option (Right to Buy) Award $0 +36.7K $0.00 36.7K Mar 14, 2025 Common Shares 36.7K $42.12 Direct F1
transaction CRSP Restricted Stock Units Award $0 +27.5K $0.00 27.5K Mar 14, 2025 Common Shares 27.5K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was granted on March 14, 2025 with respect to 36,666 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 14, 2025.
F2 Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F3 This restricted stock unit award was granted on March 14, 2025 with respect to 27,500 Common Shares, with (i) one quarter of the shares vesting on March 14, 2026, (ii) one quarter of the shares vesting on March 14, 2027, (iii) one quarter of the shares vesting on March 14, 2028, and (iv) one quarter of the shares vesting on March 14, 2029.